Clinical trials: Severe Sepsis
Septic Shock, Severe Sepsis
Restrictive Intravenous Fluids Trial in Sepsis
IV fluid resuscitation has long been recognized to be an important treatment for patients with severe sepsis and septic shock. While under-resuscitation is known to increase morbidity and mortality, contemporary data suggests…
- Trial name
- RIFTS (NCT03137446)
- Testing
- Intravenous Fluid Cap
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Rhode Island Hospital
Circulatory Shock, Sepsis
Shock and Acute Conditions OutcOmes Platform
In-hospital mortality of patients admitted in the intensive care unit (ICU) for circulatory shock remains high (between 20 and 40%).
- Conditions
- Circulatory Shock, Sepsis, Cardiogenic Shock, Major Trauma
- Trial name
- ShockCO-OP (NCT06376318)
- Testing
- Inotrope, Mechanical circulatory support, anti-bodies
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Saint-Louis Hospital, Paris, France
Severe Sepsis With Septic Shock
VTE Incidence in Severe Sepsis and Septic Shock
Prospective studies on the incidence of VTE during severe sepsis and septic shock remain absent, hindering efficacy assessments regarding current VTE prevention strategies in septic patients.
- Trial name
- NCT02353910
- Testing
- Ultrasound
- Volunteers
- 113 people
- Sponsor
- University of Utah
Severe Sepsis, Inflammatory Response Syndrome, Systemic
Following of Myeloid-derived Suppressor Cells (MDSC) in Severe Sepsis: What Relationship With Systemic Inflammatory Syndrome?
Sepsis remains a major cause of death in developed countries. A better understanding of the mechanisms involved in the regulation of inflammatory and immune response of patients with severe sepsis is an important step that could…
- Trial name
- MDSC (NCT02903082)
- Testing
- Residue of blood further to NFS, Residue of blood further to preoperative workup, Bone marrow collected during a myelogram carried out for hematological pathology workup
- Where
- France
- Volunteers
- 68 people
- Sponsor
- University Hospital, Limoges
Candidemia, Aspergillosis Invasive
Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)
Invasive fungal infections (IFI) are a major concern for immunocompromised or vulnerable patients. Associated mortality is significant and depends on the timeliness of diagnostic and therapeutic management.
- Conditions
- Candidemia, Aspergillosis Invasive, Pneumocystosis; Pneumonia (Etiology), IFI
- Trial name
- NCT07272915
- Testing
- Beta-1,3/1,6-D-Glucan
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Central Hospital, Nancy, France
Gram-Negative Bacterial Infections, Sepsis
A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult
Sepsis sometimes occurs in people who have a serious infection. It is caused by toxic substances (toxins) from bacteria and other germs entering your bloodstream.
- Trial name
- NCT00563134
- Testing
- GR270774
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Hospital Authority, Hong Kong
Severe Sepsis, Septic Shock
A Non-invasive Approach to the Assessment of Volume Status in Mechanically Ventilated Septic Patients.
To evaluate the use of sonographic inferior caval vein assessment in mechanically ventilated septic patients. Volume assessment in mechanically ventilated patients with inflammation is of major importance to guide fluid therapy.
- Trial name
- NCT00398736
- Testing
- sonographic measurement of inferior caval vein diameter
- Sponsor
- Charite University, Berlin, Germany
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Severe
Low-Sodium Diet for Postpartum Blood Pressure Control
The goal of this randomized controlled trial is to learn if a low-sodium diet improves postpartum blood pressure control in adults who were diagnosed with a late-onset hypertensive disorder of pregnancy.
- Conditions
- Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Severe, Pre-Eclampsia; Mild, Postpartum
- Trial name
- NCT07752056
- Testing
- Low Sodium Diet
- Volunteers
- 110 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Shock Hypovolemic, Shock, Septic
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths.
- Conditions
- Shock Hypovolemic, Shock, Septic, Blood Transfusion, Adrenaline
- Trial name
- NCT04750070
- Testing
- Blood and Dopamine, Blood and adrenaline
- Where
- Bangladesh
- Volunteers
- 135 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Subarachnoid Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal
Detecting Sepsis in Patients With Severe Subarachnoideal Hemorrhage
The study aims to evaluate the suitability of the SOFA score implemented by the Sepsis 3 guideline to detect sepsis in patients suffering from subrarachnoid hemorrhage.
- Conditions
- Subarachnoid Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal, Sepsis Syndrome, Sepsis
- Trial name
- NCT05246969
- Testing
- Sepsis detection
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Goethe University
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento
Sepsis, Acute Infection
Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine
The primary objective of the IMPACT-NAC trial is to assess the effects of N-acetylcysteine on survival and hospital length of stay in adults admitted to the emergency department with acute infection or sepsis and evidence of…
- Conditions
- Sepsis, Acute Infection, Severe Infection
- Trial name
- IMPACT-NAC (NCT07273071)
- Testing
- N-Acetylcysteine (NAC) Treatment
- Where
- Denmark
- Volunteers
- 360 people
- Sponsor
- Theis S. Itenov
Sepsis, Severe Sepsis
Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis
This is an observational study to understand the changes in alveolar dead space in medical critically ill patients with severe infection (severe sepsis) requiring mechanical ventilation and the possibility to predict multi-organ…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock, Multi-organ Failure
- Trial name
- NCT01315782
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Severe Sepsis
Zinc Therapy in Critical Illness
Sepsis is a clinical syndrome often caused by a bloodstream infection that results in a common set of symptoms termed systemic inflammatory response syndrome (SIRS).
- Trial name
- NCT01162109
- Testing
- Zinc sulfate
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Severe Sepsis, Acute Lung Injury
Citrulline in Severe Sepsis
This is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate biochemical, clinical, and safety effects of 2 doses of intravenous L-citrulline compared to placebo in patients with severe sepsis at risk for or…
- Trial name
- NCT01474863
- Testing
- High Dose Citrulline, Low Dose Citrulline
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Vanderbilt University
Severe Sepsis, Septic Shock
(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis
This prospective randomized multicenter study evaluates whether the decision to prescribe antifungals guided by (1,3)-β-D-glucan in comparison to standard of care shortens time to antifungal therapy and reduces mortality in…
- Trial name
- CandiSep (NCT02734550)
- Testing
- Standard of care, (1,3)-β-D-glucan guided therapy
- Where
- 18 sites in Germany
- Volunteers
- 342 people
- Sponsor
- Center for Sepsis Control and Care, Germany
Staphylococcus Lugdunensis, Bacteremia
Virulence of Staphylococcus Lugdunensis in Severe Infections
The main objective is to identify new virulence factors produced by Staphylococcus lugdunensis that can be associated with clinical sign of severe infections and identified symptoms.
- Conditions
- Staphylococcus Lugdunensis, Bacteremia, Endocarditis, Virulence Factors
- Trial name
- VISLISI (NCT02026895)
- Testing
- Genetic blood sample
- Where
- France
- Volunteers
- 82 people
- Sponsor
- University Hospital, Strasbourg, France
Sepsis, Severe Sepsis
ED Tracking Sheet Implementation
The purpose of this study is to assess whether implementation of an ED Sepsis Tracking Sheet effects the percentage of goal-directed sepsis criteria met in a tertiary care academic Emergency Department.
- Conditions
- Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome
- Trial name
- NCT05213923
- Testing
- ED Sepsis Tracking Sheet
- Where
- United States
- Volunteers
- 194 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Severe Sepsis
Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)
In this trial, patients with severe sepsis and low protein C levels will receive drotrecogin alfa (activated) at the normal, approved dose and time of administration [24 microgram/kilogram/hour (mcg/kg/hour) for 96 hours] or will…
- Trial name
- NCT00386425
- Testing
- Drotrecogin alfa (activated)
- Where
- 47 sites in United States, Belgium and 7 more
- Volunteers
- 486 people
- Sponsor
- Eli Lilly and Company